1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Male Sexual Dysfunction – Pipeline Review, H1 2013

Male Sexual Dysfunction – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 149 pages

Male Sexual Dysfunction – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Male Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Male Sexual Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Male Sexual Dysfunction.
- A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Male Sexual Dysfunction pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Male Sexual Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Male Sexual Dysfunction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Male Sexual Dysfunction - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Male Sexual Dysfunction Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Male Sexual Dysfunction 9
Male Sexual Dysfunction Therapeutics under Development by Companies 11
Male Sexual Dysfunction Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Male Sexual Dysfunction Therapeutics - Products under Development by Companies 20
Male Sexual Dysfunction Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Male Sexual Dysfunction Therapeutics Development 24
Sanofi-Aventis 24
GlaxoSmithKline plc 25
Acorda Therapeutics, Inc. 26
Chong Kun Dang Pharmaceutical 27
Dong-A Pharmaceutical Co., Ltd. 28
Mitsubishi Tanabe Pharma Corporation 29
VIVUS, Inc. 30
Bayer AG 31
IntelGenx Technologies Corp. 32
Can-Fite BioPharma Ltd. 33
NexMed, Inc. 34
NovaDel Pharma, Inc. 35
Palatin Technologies, Inc. 36
Yuhan Corporation 37
Futura Medical plc. 38
Plethora Solutions Holdings plc 39
Rexahn Pharmaceuticals, Inc. 40
Global Health Ventures Inc. 41
Fabre-Kramer Pharmaceuticals, Inc. 42
Pantarhei Bioscience BV 43
Medisyn Technologies, Inc. 44
NeuroHealing Pharmaceuticals Inc. 45
Ampio Pharmaceuticals, Inc. 46
Male Sexual Dysfunction - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
avanafil - Drug Profile 53
(lidocaine + prilocaine) - Drug Profile 55
(lidocaine + prilocaine) - Drug Profile 56
PL-6983 - Drug Profile 57
TGWOO-AA - Drug Profile 58
TGHW-01AP - Drug Profile 59
alprostadil - Drug Profile 60
alprostadil - Drug Profile 63
alfuzosin hydrochloride - Drug Profile 66
bremelanotide - Drug Profile 68
sildenafil citrate - Drug Profile 70
clavulanic acid IR - Drug Profile 72
sildenafil citrate - Drug Profile 74
GGF-2 - Drug Profile 76
CKD-533 - Drug Profile 78
modafinil - Drug Profile 79
(alprostadil + prazosin hydrochloride) - Drug Profile 80
epoetin alfa - Drug Profile 81
udenafil - Drug Profile 82
DA-8031 - Drug Profile 84
epelsiban besylate - Drug Profile 85
dapoxetine hydrochloride - Drug Profile 87
INT-0007 - Drug Profile 89
nelociguat - Drug Profile 90
(oxytocin + estrogen) - Drug Profile 92
clomipramine hydrochloride - Drug Profile 93
PDE5 Inhibitor - Drug Profile 94
MC4R Agonist - Drug Profile 95
Drug For Premature Ejaculation - Drug Profile 96
sildenafil citrate - Drug Profile 97
tramadol hydrochloride - Drug Profile 99
MCS-5 - Drug Profile 101
YHD-1023 - Drug Profile 102
(selegiline + PDE-5 Inhibitor) - Drug Profile 103
TUC-204 - Drug Profile 105
AP-102 - Drug Profile 106
Vitalon - Drug Profile 107
S1P-205 - Drug Profile 108
aildenafil - Drug Profile 109
S1B-3006 - Drug Profile 110
nitric oxide Nanoparticles For Erectile Dysfunction - Drug Profile 111
Drug For Sexual Dysfunction - Drug Profile 112
NCE-405 - Drug Profile 113
sildenafil citrate - Drug Profile 114
Male Sexual Dysfunction Therapeutics - Drug Profile Updates 115
Male Sexual Dysfunction Therapeutics - Discontinued Products 135
Male Sexual Dysfunction Therapeutics - Dormant Products 136
Male Sexual Dysfunction - Product Development Milestones 139
Featured News and Press Releases 139
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 146
Disclaimer 146



List of Tables

Number of Products Under Development for Male Sexual Dysfunction, H1 2013 12
Products under Development for Male Sexual Dysfunction - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Development by Companies, H1 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Sanofi-Aventis, H1 2013 27
GlaxoSmithKline plc, H1 2013 28
Acorda Therapeutics, Inc., H1 2013 29
Chong Kun Dang Pharmaceutical, H1 2013 30
Dong-A Pharmaceutical Co., Ltd., H1 2013 31
Mitsubishi Tanabe Pharma Corporation, H1 2013 32
VIVUS, Inc., H1 2013 33
Bayer AG, H1 2013 34
IntelGenx Technologies Corp., H1 2013 35
Can-Fite BioPharma Ltd., H1 2013 36
NexMed, Inc., H1 2013 37
Palatin Technologies, Inc., H1 2013 39
Yuhan Corporation, H1 2013 40
Futura Medical plc., H1 2013 41
Plethora Solutions Holdings plc, H1 2013 42
Rexahn Pharmaceuticals, Inc., H1 2013 43
Global Health Ventures Inc., H1 2013 44
Fabre-Kramer Pharmaceuticals, Inc., H1 2013 45
Pantarhei Bioscience BV, H1 2013 46
Medisyn Technologies, Inc., H1 2013 47
NeuroHealing Pharmaceuticals Inc., H1 2013 48
Ampio Pharmaceuticals, Inc., H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 55
Male Sexual Dysfunction Therapeutics - Drug Profile Updates 118
Male Sexual Dysfunction Therapeutics - Discontinued Products 138
Male Sexual Dysfunction Therapeutics - Dormant Products 139
Male Sexual Dysfunction Therapeutics - Dormant Products (Contd..1) 140
Male Sexual Dysfunction Therapeutics - Dormant Products (Contd..2) 141



List of Figures

Number of Products under Development for Male Sexual Dysfunction, H1 2013 12
Products under Development for Male Sexual Dysfunction - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Route of Administration, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Molecule Type, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 55

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016’, provides in depth analysis on Adenosine Recepto ...

Diabetic Neuropathy - Pipeline Review, H2 2016

Diabetic Neuropathy - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Diabetic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy – Pipeline Review, H2 2016, provides an ...

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • September 2016
  • by Global Markets Direct

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2016’, provides an overview ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.